The objective of this study was to determine the effect of care in the home (CHM) compared with usual care (UC) in patients with chronic heart failure (CHF) on clinical outcomes and healthcare use including a cost-effectiveness analysis.
A systematic literature search on MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health Literature, the Cochrane Library, as well as Centre for Reviews and Dissemination was conducted to identify randomized controlled trials comparing CHM with UC in CHF. The randomized controlled trials meeting inclusion criteria were meta-analyzed by outcome, and the quality of evidence for each outcome was evaluated using Grading of Recommendations Assessment, Development, and Evaluation system. A cost-effectiveness model was developed to estimate costs and quality-adjusted life years.
Six randomized controlled trials were identified from 1277 citations. Care in the home was predominately provided by a single health professional consisting of nurse-led education of varying duration and frequency. One study included pharmacist-led CHM. Care in the home showed a decreased risk for all-cause mortality and hospitalizations combined (risk ratio, 0.88; 95% confidence interval [CI], 0.80–0.97), but not all-cause mortality alone (risk ratio, 0.92; 95% CI, 0.81–1.04). Care in the home resulted in fewer hospitalizations (mean difference, −1.03; 95% CI, −1.53 to −0.53) and fewer emergency department visits (mean difference, −1.32; 95% CI, −1.87 to −0.77). Quality of life also improved with CHM delivered by nurses. Critical appraisal of the quality of evidence suggests uncertainty in the estimates for a number of outcomes. Care in the home resulted in a savings of $10,665 and a gain of 0.11 quality-adjusted life years compared with UC.
In conclusion, the beneficial effect of CHM in CHF is by reducing mortality and hospitalizations combined. Care in the home in CHF seems to be more effective and less costly compared with UC.
Jennifer Fergenbaum, PhD Clinical Epidemiologist, Health Quality Ontario, Evidence Development and Standards Branch, Toronto, Canada.
Sarah Bermingham, MSc Health Economist, Health Quality Ontario, Evidence Development and Standards Branch, Toronto, Canada; and The Toronto Health Economic and Technology Assessment (THETA) Collaborative, Ontario, Canada.
Murray Krahn, MD Director, The Toronto Health Economic and Technology Assessment (THETA) Collaborative, Ontario, Canada.
David Alter, MD Senior Scientist and Cardiologist, Department of Medicine, University of Toronto, Cardiologist, Toronto Rehabilitation Institute-University Health Network, Institute for Clinical Evaluative Sciences, Ontario, Canada.
Catherine Demers, MD Cardiologist, Division of Cardiology, Department of Medicine, McMaster University, Hamilton General Hospital, Ontario, Canada.
Health Quality Ontario is sponsored by the Ontario Ministry of Health and Long-Term Care. The findings and conclusions in this article are those of the author(s) and do not necessarily represent the views of Health Quality Ontario.
The authors have no conflicts of interest to disclose.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (www.jcnjournal.com).
Correspondence Jennifer Fergenbaum, PhD, Health Quality Ontario, Evidence Development and Standards Branch, 130 Bloor St W, 10th Flr, Toronto, Ontario, M5S 1N5 (Jennifer.Fergenbaum@hqontario.ca).